drugset
drugset / Trial / NCT03391778

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

NCT03391778 ↗

Phase 1 Recruiting 250 enrolled USWM CT, LLC
NaSingle-groupOpen-labelOther

Summary

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Timeline

Start
2018-04-09
Primary completion
2032-04-01
Completion
2032-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ADP adoptive cell therapy Cell therapy — —

Indications

neoplasm